<DOC>
	<DOCNO>NCT00039286</DOCNO>
	<brief_summary>RATIONALE : Imaging procedure positron emission tomography ( PET ) may improve ability detect extent breast cancer . PURPOSE : Diagnostic trial study effectiveness PET detect extent breast cancer woman primary recurrent breast cancer .</brief_summary>
	<brief_title>Positron Emission Tomography Before Surgery Evaluating Women With Primary Recurrent Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine sensitivity , specificity , accuracy fludeoxyglucose F 18 ( FDG ) positron emission tomography ( PET ) compare conventional image determine extent disease woman primary recurrent breast cancer . - Determine often clinical management operative intervention plan patient alter base FDG-PET scan finding . - Determine whether FDG-PET result accurate detection disease patient . OUTLINE : Patients receive fludeoxyglucose F 18 IV . Approximately 1 hour later , patient undergo positron emission tomography imaging . Some patient may undergo repeat scan 4-6 month . PROJECTED ACCRUAL : ( 50 primary disease 50 recurrent disease ) accrue study within 1-2 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Fluorodeoxyglucose F18</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis breast cancer surgical intervention plan Large primary breast cancer ( i.e. , large 5 cm , T3 ) determine prior biopsy , physical exam , mammogram OR Locally advance breast cancer ( T4 ) OR Clinical suspicion axillary nodal disease ( N12 ) ( i.e. , stage IIBIIIA ) OR Locally regionally recurrent disease No locally recurrent disease noninvasive ( i.e. , ductal carcinoma situ ) No locally advance disease ( e.g. , inflammatory breast cancer ) treat neoadjuvant chemotherapy without surgery Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : Not specify Sex : Female Menopausal status : Not specify Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Other : No malignancy except previously treat nonmelanoma skin cancer carcinoma situ cervix No known active infection No autoimmune disease inflammatory disease ( e.g. , sarcoidosis rheumatoid arthritis ) Able fast 6 hour tolerate FDGPET scan duration test Not pregnant nursing PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : See Disease Characteristics</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>